Terbinafine hydrochloride
Phase 2Small molecule
NovartisTerbinafine hydrochloride is one of 24 small molecule programs targeting Tinea Pedis. It is currently in Phase 2.
2
Indications
13
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in Tinea Pedis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lamisil
NovartisPhase 3
Nizoral
WWim Janssens
Phase 3
Luzu
BBausch Health Americas, Inc.
Approved
Inomax
MMallinckrodt
Phase 2
Ciclopirox Olamine
AAtlas Molecular Pharma
Phase 3
NAFT-500
MMerz North America, Inc.
Phase 3
Terbinafine hydrochloride
NovartisPhase 2
VT-1161
VViamet
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tinea Capitis2 trials
Onychomycosis2 trials
LAM2 trials
4 more indications
Effectiveness1 trial
Otomycosis1 trial
Terbinafine Hydrochloride for the Treatment of Otomycosis
Not yet recruiting·—·N/A·NCT07152327·50 enrolled
Fed1 trial
Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions
Completed·—·Phase 1·NCT01286701·18 enrolled
Fasting Conditions1 trial
Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions
Completed·—·Phase 1·NCT01286688·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Terbinafine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]